



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 63120

Title: BRCA mutated pancreatic cancer: A change is coming

Reviewer's code: 00505466

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Full Professor

Reviewer's Country/Territory: Greece

Author's Country/Territory: Canada

Manuscript submission date: 2021-01-25

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-25 07:04

Reviewer performed review: 2021-01-30 11:28

Review time: 5 Days and 4 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors provide an excellent, comprehensive and very interesting review of the role and the significance of BRCA mutations in pancreatic cancer. The manuscript is very well written and easy to read and understand, despite the specialized topic. Only some very minor comments are to be made. Page 3. 'lynch syndrome', Lynch should be written with capital L. Page 8. In 'While both FOLFIRINOX and gemcitabine/nab-paclitaxel chemotherapy regimens are more effective then gemcitabine monotherapy, ...', 'then' should be 'than'. Page 9. 'Several large retrospective studies have investigated the efficacy of platinum-based chemotherapies (PtCh) such as FOLFIRINOX specific to patients with BRCA mutations or other genetic mutations leading to HRD (Table 2).' Since the previous paragraph concerned non-pancreatic cancer, please clarify in this initial sentence that these studies were on pancreatic cancer. Page 15. 'O'reilly et al' should be 'O'Reilly et al'. Page 17. 'Niraparib' should be with lower case 'n', such as all other names of PRAP inhibitors. 'Pembrolizumab' should be with lower case 'p', such as all other names of immune check inhibitors. The following comments regarding the use of the acronyms: Page 3. Please define the acronym PDAC as pancreatic duct adenocarcinoma and not just pancreatic adenocarcinoma to justify the D in the acronym. Page 10. The acronym 'PFS' (although well known) should be defined at first appearance. Page 12. Since 'RR' has not been defined previously (only 'ORR'), please define the acronym. Page 15. Since its acronym 'OS' has been used, please replace 'overall survival' by 'OS'. Page 15. Since the acronym 'QOL' has been defined and used, later in the text 'quality of life' should be replaced by 'QOL'. Page 19, at the end of the first paragraph. 'pancreatic cancer' should be PC, as the acronym has been used and defined previously.